Limits...
A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.

Addo S, Yates RA, Laight A - Br. J. Cancer (2002)

Bottom Line: Fulvestrant ("Faslodex") is a new oestrogen receptor antagonist that downregulates the oestrogen receptor and has no known agonist effect.Neither the 125 mg nor 250 mg doses of fulvestrant demonstrated oestrogenic effects on the endometrium over the initial 14-day assessment period.Fulvestrant was well tolerated and reduced the incidence of ethinyloestradiol-related side effects.

View Article: PubMed Central - PubMed

Affiliation: LCG Bioscience, Bourn Hall Clinic, Bourn, Cambridge, UK.

Show MeSH

Related in: MedlinePlus

Study design. N.B. Fulvestrant administered as a single intramuscular injection, which provided continuous exposure over at least a 28-day period.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376292&req=5

fig1: Study design. N.B. Fulvestrant administered as a single intramuscular injection, which provided continuous exposure over at least a 28-day period.

Mentions: This was a double-blind, randomised, parallel-group, single-centre trial in healthy, postmenopausal volunteers (Figure 1Figure 1


A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.

Addo S, Yates RA, Laight A - Br. J. Cancer (2002)

Study design. N.B. Fulvestrant administered as a single intramuscular injection, which provided continuous exposure over at least a 28-day period.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376292&req=5

fig1: Study design. N.B. Fulvestrant administered as a single intramuscular injection, which provided continuous exposure over at least a 28-day period.
Mentions: This was a double-blind, randomised, parallel-group, single-centre trial in healthy, postmenopausal volunteers (Figure 1Figure 1

Bottom Line: Fulvestrant ("Faslodex") is a new oestrogen receptor antagonist that downregulates the oestrogen receptor and has no known agonist effect.Neither the 125 mg nor 250 mg doses of fulvestrant demonstrated oestrogenic effects on the endometrium over the initial 14-day assessment period.Fulvestrant was well tolerated and reduced the incidence of ethinyloestradiol-related side effects.

View Article: PubMed Central - PubMed

Affiliation: LCG Bioscience, Bourn Hall Clinic, Bourn, Cambridge, UK.

Show MeSH
Related in: MedlinePlus